Aug 26, 2024 7:00am EDT Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
Aug 21, 2024 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium (MHSRS)
Aug 20, 2024 7:00am EDT Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication
Aug 19, 2024 6:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
Aug 16, 2024 7:00am EDT Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
Aug 12, 2024 8:00am EDT Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain
Aug 6, 2024 8:00am EDT Tonix Pharmaceuticals Announces Publication in Microorganisms of Technology that Expands Company’s Capabilities in Generating Potential Therapeutic Fully Human Antibodies Against SARS-CoV-2 and Other Pathogens
Jul 31, 2024 8:00am EDT Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
Jul 30, 2024 8:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the IASP 2024 World Congress on Pain
